Israeli startups raise record $4.8 billion in 2016

Amount raised in the fourth quarter was down 8% from the corresponding quarter of 2015.

January 10, 2017 14:33
4 minute read.
Ramat Gan

Ramat Gan's business district.. (photo credit: REUTERS)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Israeli high-tech companies raised a record $4.8 billion in 2016, up 11% from $4.3 billion in 2015, the latest IVC - ZAG (Zysman Aharoni, Gayer & Co. law firm) survey has found. The average financing round, which has been constantly growing over the past five years, reached $7.2 million in 2016, 19% above the $5.1 million five-year average.

However, the fourth quarter of 2016 saw $1.02 billion raised in 151 transactions, down 8% from $1.11 billion in 202 deals in the corresponding quarter of 2015, but up 9% from $933 million raised in 140 deals in the preceding quarter. The average financing round stood at $6.7 million in the fourth quarter of 2016, similar to the past two-year quarterly average of $6.6 million.

IVC Research Center CEO Koby Simana said, "As expected, 2016 ended as a record year in Israeli high-tech capital raising. However, despite the higher total amount, it was characterized by a smaller number of financing rounds, along with a higher average capital raising per round. When we looked into the numbers to try and explain the trend, we found what I would call a ‘B Crunch’ - a 30% drop in the number of second rounds closed in 2016 compared to 2015, while the number of earlier rounds slightly increased. This is a troubling trend for the Israeli VC funnel, since the majority of capital goes into later rounds - if there are no companies lined up for later investments, there could be a more serious issue later on."

The IVC-ZAG Survey reveals that, while capital-raising reached new heights in 2016, the number of financing rounds were fewer than expected, with 659 deals closed in 2016, marginally above the five-year average of 657 deals, and 7% below 2015’s record 706 deals. While the number of early rounds (seed and A rounds) increased slightly (5%), the number of B rounds dropped 30% and the number of later rounds - C or higher - was responsible for more than 60% of the capital, down 11% from 2015. B rounds' share of capital raising also decreased, falling from 25% in 2015 ($1.07 billion) to 16% in 2016 ($743 million), while early rounds and later rounds generated more capital and took up larger shares than the year before.

The IVC-ZAG Survey also reveals an upsurge in large deals (above $20 million) in 2016, both in terms of deal number and capital raised - with 76 deals and $2.68 billion, respectively - a 22% increase from the $2.19 billion raised in 68 deals in 2015.

Adv. Oded Har-Even, ZAG-S&W (Zysman Aharoni Gayer & Co. ) partner responsible for its US office, offers a possible explanation, "The increase in capital raising in mid- to late stages could imply a growing use of mezzanine funding in mature companies, gearing towards a possible M&A or IPO (preferably on NASDAQ). If this is indeed the case, then it's a very welcome trend, revealing a mature market considered to be on the ‘quick exit route’ following early stage investments."

Adv, Shmulik Zysman, founding partner of ZAG-S&W (Zysman, Aharoni, Gayer & Co.) agrees, adding: "We expect the uptrend in capital raising activity to continue in 2017, though possibly at slower rates."

Fifteen deals above $20 million reached a total of $573 million, or 56%, of all capital raised in the fourth quarter of 2016. This compares with $430 million (38%), raised in 14 deals in the corresponding quarter of 2015, and $517 million (55%) raised in 18 transactions in the preceding quarter of 2016.

Israeli VC fund investment activity

Israeli venture capital funds invested a total of $634 million in Israeli high-tech companies in 2016, slightly up from $627 million invested in 2015. In the past five years, Israeli venture capital fund investments steadily increased, from $482 million in 2012 to the current level. At the same time, their share of total capital invested has been decreasing gradually, from 26% in 2012 down to 13% in 2016, the lowest yet.

In the fourth quarter of 2016, $111 million was invested by Israeli venture capital funds in local high-tech companies, 44% below the $198 million invested in the corresponding quarter of 2015 and 20% below the $139 million invested in the preceding quarter of 2016. Israeli venture capital funds' share was down to 11% in the fourth quarter of 2016, from 18% and 15% in the corresponding quarter of 2015 and the preceding quarter of 2016, respectively.

Capital raised by sector

Software companies led capital-raising in 2016 with $1.7 billion, up from 2015 when the sector attracted $1.4 billion (32%), also placing first. Internet capital raising has noticeably decreased in 2016, when the sector attracted only $744 million or a mere 16% of total capital, compared with $1.12 billion raised in 2015, when Internet placed second with a 26% share.

Zysman observed that there was a 14% fall in life science capital raising in 2016. "Despite the decrease in life science capital raising in 2016, we remain optimistic with regards to the industry’s potential in Israel, due to three major reasons: the continuous interest shown by Chinese investors, good chances for the return of European and US investors to Israeli life science investments, and Donald Trump's imminent presidency. According to his campaign, Trump is expected to ease price control on drugs and medical services, bringing an optimistic note to the industry, which may increase the appetite for investments, Israel included."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Workers strike outside of the Teva building in Jerusalem, December 2017
December 18, 2017
Workers make explosive threats as massive Teva layoff strikes continue


Cookie Settings